BACKGROUND: Patients with colorectal liver metastases (CRLM) who are ineligible for curative surgery are potential candidates for radiofrequency ablation (RFA). Although RFA has emerged as a well accepted and documented treatment modality, there are still some reservations because of initially high rates of local site recurrences (LSR). The aim of the present study was to evaluate LSR levels following RFA treatment, with a specific focus on re-treatment and survival. PATIENTS AND METHODS: All patients ineligible for curative resection of CRLM and undergoing RFA alone or in combination with resection were prospectively included from July 2000 to December 2010 and retrospectively analyzed. Patients with untreatable extrahepatic disease were excluded. FDG PET-CT was conducted at 3-6 month intervals after RFA. Patients with LSR were evaluated for re-treatment. RESULTS: A total of 132 patients were treated with RFA, which was combined with resection in 64 patients. A total of 290 lesions were ablated, with a mean number of 2.19 per patient and a mean size of 2.2 cm. Median survival was 41 months, with a 3- and 5-year survival of, respectively, 60 and 30.8 %. Following initial RFA, 39 patients developed an LSR in 40 ablated lesions, and local recurrence was strongly related to lesion size. Re-treatment could be performed in 26/39 patients, of whom eight remained disease-free. CONCLUSIONS: Radiofrequency ablation can be applied to CRLM of less than 3 cm with curative intent. In the absence of extensive intrahepatic or extrahepatic disease, renewed treatment of local recurrences should be considered and is often successful.
BACKGROUND:Patients with colorectal liver metastases (CRLM) who are ineligible for curative surgery are potential candidates for radiofrequency ablation (RFA). Although RFA has emerged as a well accepted and documented treatment modality, there are still some reservations because of initially high rates of local site recurrences (LSR). The aim of the present study was to evaluate LSR levels following RFA treatment, with a specific focus on re-treatment and survival. PATIENTS AND METHODS: All patients ineligible for curative resection of CRLM and undergoing RFA alone or in combination with resection were prospectively included from July 2000 to December 2010 and retrospectively analyzed. Patients with untreatable extrahepatic disease were excluded. FDG PET-CT was conducted at 3-6 month intervals after RFA. Patients with LSR were evaluated for re-treatment. RESULTS: A total of 132 patients were treated with RFA, which was combined with resection in 64 patients. A total of 290 lesions were ablated, with a mean number of 2.19 per patient and a mean size of 2.2 cm. Median survival was 41 months, with a 3- and 5-year survival of, respectively, 60 and 30.8 %. Following initial RFA, 39 patients developed an LSR in 40 ablated lesions, and local recurrence was strongly related to lesion size. Re-treatment could be performed in 26/39 patients, of whom eight remained disease-free. CONCLUSIONS: Radiofrequency ablation can be applied to CRLM of less than 3 cm with curative intent. In the absence of extensive intrahepatic or extrahepatic disease, renewed treatment of local recurrences should be considered and is often successful.
Authors: A A J M Van Tilborg; M R Meijerink; C Sietses; J H T M Van Waesberghe; M O Mackintosh; S Meijer; C Van Kuijk; P Van Den Tol Journal: Br J Radiol Date: 2010-12-15 Impact factor: 3.039
Authors: Simon S Lo; Achilles J Fakiris; Eric L Chang; Nina A Mayr; Jian Z Wang; Lech Papiez; Bin S Teh; Ronald C McGarry; Higinia R Cardenes; Robert D Timmerman Journal: Nat Rev Clin Oncol Date: 2009-12-08 Impact factor: 66.675
Authors: T J Blokhuis; M C van der Schaaf; M P van den Tol; E F I Comans; R A Manoliu; J R M van der Sijp Journal: Scand J Gastroenterol Suppl Date: 2004
Authors: Robert Martin; Philip Paty; Yuman Fong; Andrew Grace; Alfred Cohen; Ronald DeMatteo; William Jarnagin; Leslie Blumgart Journal: J Am Coll Surg Date: 2003-08 Impact factor: 6.113
Authors: T J White; S H Roy-Choudhury; D J Breen; J Cast; A Maraveyas; E F Smyth; J E Hartley; J R T Monson Journal: Dig Surg Date: 2004-09-13 Impact factor: 2.588
Authors: Mechteld C de Jong; Skye C Mayo; Carlo Pulitano; Serena Lanella; Dario Ribero; Jennifer Strub; Catherine Hubert; Jean-François Gigot; Richard D Schulick; Michael A Choti; Luca Aldrighetti; Gilles Mentha; Lorenzo Capussotti; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2009-10-01 Impact factor: 3.452
Authors: Matthew T Seymour; Timothy S Maughan; Jonathan A Ledermann; Clare Topham; Roger James; Stephen J Gwyther; David B Smith; Stephen Shepherd; Anthony Maraveyas; David R Ferry; Angela M Meade; Lindsay Thompson; Gareth O Griffiths; Mahesh Kb Parmar; Richard J Stephens Journal: Lancet Date: 2007-07-14 Impact factor: 79.321
Authors: H J Scheffer; K Nielsen; A A J M van Tilborg; J M Vieveen; R A Bouwman; G Kazemier; H W M Niessen; S Meijer; C van Kuijk; M P van den Tol; M R Meijerink Journal: Eur Radiol Date: 2014-06-18 Impact factor: 5.315
Authors: Karin Nielsen; Hester J Scheffer; José H Volders; Maurice J D L van der Vorst; Aukje A J M van Tilborg; Emile Fi Comans; E S M de Lange-de Klerk; Colin Sietses; Sybren Meijer; Martijn R Meijerink; M Petrousjka van den Tol Journal: World J Surg Date: 2016-08 Impact factor: 3.352
Authors: Alice Gillams; Nahum Goldberg; Muneeb Ahmed; Reto Bale; David Breen; Matthew Callstrom; Min Hua Chen; Byung Ihn Choi; Thierry de Baere; Damian Dupuy; Afshin Gangi; Debra Gervais; Thomas Helmberger; Ernst-Michael Jung; Fred Lee; Riccardo Lencioni; Ping Liang; Tito Livraghi; David Lu; Franca Meloni; Philippe Pereira; Fabio Piscaglia; Hyunchul Rhim; Riad Salem; Constantinos Sofocleous; Stephen B Solomon; Michael Soulen; Masatoshi Tanaka; Thomas Vogl; Brad Wood; Luigi Solbiati Journal: Eur Radiol Date: 2015-05-22 Impact factor: 5.315
Authors: Karin Nielsen; Hester J Scheffer; Indra C Pieters; Aukje A J M van Tilborg; Jan-Hein T M van Waesberghe; Daniela E Oprea-Lager; Martijn R Meijerink; Geert Kazemier; Otto S Hoekstra; Hermien W H Schreurs; Colin Sietses; Sybren Meijer; Emile F I Comans; Petrousjka M P van den Tol Journal: BMC Med Imaging Date: 2014-08-08 Impact factor: 1.930